Publication:
Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.

Thumbnail Image
Identifiers
URI: http://hdl.handle.net/20.500.12105/18634
ISSN: 2072-6694
DOI: 10.3390/cancers14092255
Full text access: http://hdl.handle.net/10668/20890

Publication date

2022-04-30

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publishers

Metrics
Google Scholar
Export
MarcXML METS

Research Projects

Organizational Units

Journal Issue

Abstract

Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.

Description

Keywords

NK-1R cancer drug repurposing personalized medicine resistance tachykinin tachykinin receptor targeted treatment

MeSH Terms

DeCS Terms

Bibliographic citation

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)

Publisher version

Related dataset

Related publication

Document type

research article